Description:
TAY-SACHS DISEASE; TSD
HEXOSAMINIDASE A; HEXA
GLUCOSIDASE, ACID BETA; GBA
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases Lysosomal Storage Diseases |
Class |
Disorders of Lipid Metabolism |
Cell Type
|
Fibroblast
|
Transformant
|
Untransformed
|
Race
|
White
|
Ethnicity
|
JEWISH
|
Relation to Proband
|
proband
|
Confirmation
|
Clinical summary/Case history
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
Passage Frozen |
2 |
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Nucleoside Phosphorylase Isoenzyme Electrophoresis |
|
URACIL DNA GLYCOSYLASE |
Seal et al (Proc Natl Acad Sci USA 85:2339-2343, 1988) reported that monoclonal antibody, 40.10.09 to normal uracil DNA glycosylase had normal immunoreactivity with the uracil DNA glycosylase from this cell culture. In contrast, the antibody did not recognize or inhibit the native enzyme from five different Bloom syndrome cultures. |
|
Gene |
GBA |
Chromosomal Location |
1q21 |
Allelic Variant 1 |
606463.0003; GAUCHER DISEASE, TYPE I |
Identified Mutation |
ASN370SER; By nucleotide sequence analysis of a genomic clone from an Ashkenazi Jewish patient with type I, Tsuji et al. [Proc. Nat. Acad. Sci. 85: 2349-2352 (1988] found a single-base mutation (adenosine to guanosine transition) in exon 9 of the glucocerebrosidase gene. This change resulted in the amino acid substitution of serine for asparagine. Transient expression studies following oligonucleotide-directed mutagenesis of the normal cDNA confirmed that the mutation results in loss of glucocerebrosidase activity. This mutation [1226G (N370S)] accounts for approximately 70% of mutations in the Jewish population. |
|
Gene |
HEXA |
Chromosomal Location |
15q23-q24 |
Allelic Variant 1 |
606869.0001; TAY-SACHS DISEASE |
Identified Mutation |
c.1274_1277dupTATC; Myerowitz and Costigan [J Biol Chem 263: 18587 (1988)] demonstrated that the most frequent DNA lesion in Tay-Sachs disease of Ashkenazi Jews is a 4-bp insertion in exon 11. This mutation introduces a premature termination signal in exon 11, resulting in a deficiency of mRNA. This is the most frequent defect underlying Tay-Sachs disease in the Ashkenazi Jewish population. This mutation is alternatively designated 1277TATC; see 272800.0054. |
|
Gene |
HEXA |
Chromosomal Location |
15q23-q24 |
Allelic Variant 2 |
606869.0035; BETA-HEXOSAMINIDASE A, PSEUDODEFICIENCY OF |
Identified Mutation |
ARG247TRP; Triggs-Raine et al. (1992) identified a C-to-T transition at nucleotide 739, resulting in an arg247-to-trp substitution as the basis of pseudodeficiency of beta-hexosaminidase A. This allele accounted for 32% (20/62) of non-Jewish enzyme-defined Tay-Sachs disease carriers but for none of 36 Jewish enzyme-defined carriers who did not have one of the 3 known mutations common to the Jewish group. In combination with a 'true' Tay-Sachs disease allele, the arg247-to-trp allele causes HEXA pseudodeficiency. Given both the large proportion of non-Jewish carriers with this allele and the fact that standard biochemical screening cannot differentiate between heterozygotes for the arg247-to-trp mutation and Tay-Sachs disease carriers, DNA testing for this mutation in at-risk couples is essential. Contrary to the findings of Triggs-Raine et al. (1992) of no cases of the C739-to-T pseudodeficiency allele among Jewish carriers, Tomczak et al. (1993) found that of 33 carriers who had none of the 3 common mutations, the pseudodeficiency mutation was present in 6 of 19 Jews and 8 of 14 non-Jews. Tomczak et al. (1993) suggested that DNA analysis should be part of a comprehensive screening program because 2 mutant alleles, the pseudodeficiency allele and the adult allele, are indistinguishable from the lethal infantile mutations by means of enzyme assay yet have very different phenotypic significance and together may account for as many as 12% of enzyme-defined carriers.
|
Remarks |
Ashkenazi; clinically normal; possible variant; 25% normal hexosaminidase A in leukocytes, 9% in fibroblasts, and none in serum or plasma; both parents have heterozygous levels of hexosaminidase A; donor subject is heterozygous for a 4-bp insertion at nucleotide 1278 in exon 11 of the HEXA gene [1278insTATC] that introduces a premature termination signal in the exon resulting in deficiency of mRNA and heterozygous for a benign C>T mutation at nucleotide 739 in exon 7 (739C>T) resulting in the substitution of tryptophan for arginine at codon 247 [Arg247Trp (R247W)]; donor subject also is heterozygous for an A>G transition at nucleotide 1226 in exon 9 of the GBA gene (1226A>G) resulting in a substitution of serine for asparagine at codon 370 [Asn370Ser (N370S)] [codons are numbered from the first codon of the mature protein; the cDNA is numbered from the first initiating AUG] |
Kalman L, Wilson JA, Buller A, Dixon J, Edelmann L, Geller L, Highsmith WE, Holtegaard L, Kornreich R, Rohlfs EM, Payeur TL, Sellers T, Toji L, Muralidharan K, Development of genomic DNA reference materials for genetic testing of disorders common in people of ashkenazi jewish descent The Journal of molecular diagnostics : JMD11:530-6 2009 |
PubMed ID: 19815695 |
|
Cao Z, Petroulakis E, Salo T, Triggs-Raine B, Benign HEXA mutations, C739T(R247W) and C745T(R249W), cause beta-hexosaminidase A pseudodeficiency by reducing the alpha-subunit protein levels. J Biol Chem272:14975-82 1997 |
PubMed ID: 9169471 |
|
Seal G, Brech K, Karp SJ, Cool BL, Sirover MA, Immunological lesions in human uracil DNA glycosylase: association with Bloom syndrome. Proc Natl Acad Sci U S A85:2339-43 1988 |
PubMed ID: 3353381 |
|
Grebner, An altered form of hexosaminidase A. Am J Hum Genet33:44A (1981):2339-43 1981 |
PubMed ID: 3353381 |
dbSNP |
dbSNP ID: 20436 |
Gene Cards |
GBA |
|
HEXA |
Gene Ontology |
GO:0004348 glucosylceramidase activity |
|
GO:0004563 beta-N-acetylhexosaminidase activity |
|
GO:0005764 lysosome |
|
GO:0005975 carbohydrate metabolism |
|
GO:0006665 sphingolipid metabolism |
|
GO:0006687 glycosphingolipid metabolism |
|
GO:0007040 lysosome organization and biogenesis |
|
GO:0016020 membrane |
|
GO:0016798 hydrolase activity, acting on glycosyl bonds |
NCBI Gene |
Gene ID:2629 |
|
Gene ID:3073 |
NCBI GTR |
272800 TAY-SACHS DISEASE; TSD |
|
606463 GLUCOSIDASE, BETA, ACID; GBA |
|
606869 HEXOSAMINIDASE A; HEXA |
OMIM |
272800 TAY-SACHS DISEASE; TSD |
|
606463 GLUCOSIDASE, BETA, ACID; GBA |
|
606869 HEXOSAMINIDASE A; HEXA |
Omim Description |
B VARIANT GM2 GANGLIOSIDOSIS |
|
GM2-GANGLIOSIDOSIS, ADULT CHRONIC TYPE, INCLUDED |
|
GM2-GANGLIOSIDOSIS, TYPE I |
|
HEXA DEFICIENCYHEXOSAMINIDASE A, INCLUDED; HEXA, INCLUDED |
|
HEXOSAMINIDASE A DEFICIENCY |
|
HEXOSAMINIDASE A DEFICIENCY, ADULT TYPE, INCLUDED |
|
TAY-SACHS DISEASE, JUVENILE, INCLUDED |
|
TAY-SACHS DISEASE, PSEUDO-AB VARIANT, INCLUDED |
|
TAY-SACHS DISEASE, VARIANT B1, INCLUDED |
|
TAY-SACHS DISEASE; TSD |
Passage Frozen |
2 |
Split Ratio |
1:5 |
Temperature |
37 C |
Percent CO2 |
5% |
Percent O2 |
AMBIENT |
Medium |
Eagle's Minimum Essential Medium with Earle's salts and non-essential amino acids with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not inactivated |
Substrate |
None specified |
Subcultivation Method |
trypsin-EDTA |
Supplement |
- |
|
|